GlaxoSmithKline three–in–one inhaler lung drug has received positive feedback from European Medicine Agency on September 15, paving the way for its use in the treatment of patients with severe chronic obstructive pulmonary disease( COPD).
GlaxoSmithKlin's (GSK) inhaler uses three types of drugs including fluticasonroate, umeclidinium and vilanterol. The company is pitching for the new inhaler which has been designed to help patients withstand COPD.
GSK and US-listed Innoviva received a positive response to the treatment from the EMA's Conmmittee for Medicinal Products for Human Use (CHMP), stated GSK in a statement.
The positive feedback from EMA forms one of the final steps before seeking authorization for marketing the product, especially in Europe. The final nod will come by the end of 2017, said the company.
The company's intial lung drug Advair, which has generated more than $1 billion during the annual sales since 2001, is currently facing generic competition in Europe. The company failed to get the US approval for the product due to its lower price and hoping to get a nod by mid-2018.
Otherwise, Emma Walmsley , GSK's new chief executive recently declared plans to allocate 80% of its Research and Development budget in the future to respiratory and HIV diseases on July 26, 2017.
